Trends in surgical procedures for bladder cancer within the Brazilian public health system: An 11-year analysis

Background: Continuous updates to procedures and hospital admissions for bladder cancer (BC) are crucial for understanding trends, particularly within Brazil’s public health system. Monitoring these data is vital for informed decision-making. Objective: The objective of the study was to understand the trends in surgical procedures for BC within the Brazilian public health system. Methods: Data were collected from the Brazilian Data Center for the Public Health System, focusing on hospital admissions related to bladder surgeries from 2013 to 2023. Information was categorized in terms of procedure urgency, hospitalization duration, costs, and mortality rates. Results: A total of 123,434 BC-related surgical procedures were performed, the majority of which were elective (73.4%) and bladder-preserving (BP, 96.2%). There were 1,710 reported mortalities, with a consistent procedure-specific mortality rate (PSMR) across the 11-year period for all procedures. The average hospitalization duration for elective BP (β = −0.12, p < 0.001), elective non-BP (β = −0.46, p < 0.001), and urgent non-BP procedures (β = −0.41, p = 0.012) steadily decreased. Elective and urgent BPs showed the lowest annual PSMRs (0.66% and 4.25%, respectively), compared to elective and urgent non-BPs (6.93% and 10.72%). The northern and northeastern regions reported significantly fewer cases but higher mortality rates after 2018, despite reduced average hospital stays. While hospital costs for these procedures increased, the standalone costs of surgical interventions remained stable over the 11-year period. Conclusion: BC-related hospital admissions, particularly for BP procedures, have increased, reflecting improved access to healthcare. However, regional disparities in surgical care, mortality rates, and hospital stays persist across Brazil.
- Global Cancer Observatory. Cancer Today. Global Cancer Observatory; 2021. Available from: https://gco.iarc.fr [Last accessed 2024 Sep 19].
- Beatrici E, Labban M, Filipas DK, et al. Smoking characteristics and years since quitting smoking of US adults diagnosed with lung and bladder cancer: A national health and nutrition examination survey analysis. Int Braz J Urol. 2024;50(2):199-208. doi: 10.1590/S1677-5538.IBJU.2023.0625
- Andrade DL, Moretti TBC, Neto WA, Benedetti J, Reis LO. Smoke load prognostic impact on Bacillus Calmette-Guérin (BCG) treated non-muscle invasive bladder cancer. Int Urol Nephrol. 2020;52(8):1471-1476. doi: 10.1007/s11255-020-02438-6
- MS. Estimativa da Incidência e Mortalidade por Câncer no Brasil. Brasil: Instituto Nacional de Câncer; 2018, 2020. Available from: https://www.inca.gov.br/sites/ufu.sti.inca. local/files/media/document/estimativa-2020-incidencia-de-cancer-no-brasil.pdf [Last accessed 2024 Sep 19].
- Avilez ND, Capibaribe DM, Reis LO. Experimental and new approaches for bladder preservation in intermediate and high-risk non-muscle-invasive bladder cancer (NMIBC). Res Rep Urol. 2024;16:89-113. doi: 10.2147/RRU.S452377
- Holzbeierlein JM, Bixler BR, Buckley DI, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline: 2024 amendment. J Urol. 2024;211(4):533-538. doi: 10.1097/JU.0000000000003846
- Babjuk M, Burger M, Capoun O, et al. European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol. 2022;81(1):75-94. doi: 10.1016/j.eururo.2021.08.010
- Alfred Witjes J, Max Bruins H, Carrión A, et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2023 guidelines. Eur Urol. 2024;85(1):17-31. doi: 10.1016/j.eururo.2023.08.016
- Siracusano S, Gontero P, Mearini E, et al. Short-term effects of bowel function on global health quality of life after radical cystectomy. Minerva Urol Nephrol. 2024;76(4):452-457. doi: 10.23736/S2724-6051.24.05730-6
- Francolini G, Ghoshal A, Caini S, et al. Quality of life after definitive treatment for bladder cancer: A systematic review and meta-analysis. Radiother Oncol. 2024;190:110038. doi: 10.1016/j.radonc.2023.110038
- Timoteo F, Korkes F, Baccaglini W, Glina S. Bladder cancer trends and mortality in the Brazilian public health system. Int Braz J Urol. 2020;46(2):224-233. doi: 10.1590/S1677-5538.IBJU.2019.0198
- Stone BV, Labban M, Filipas DK, et al. The risk of catastrophic healthcare expenditures among prostate and bladder cancer survivors in the United States. Clin Genitourin Cancer. 2023;21(6):617-625. doi: 10.1016/j.clgc.2023.05.016
- Viana SW, Faleiro MD, Mendes ALF, et al. Limitations of using the DATASUS database as a primary source of data in surgical research: A scoping review. Rev Col Bras Cir. 2023;50:e20233545. doi: 10.1590/0100-6991e-20233545-en
- Saldanha RF, Bastos RR, Barcellos C. Microdatasus: A package for downloading and preprocessing microdata from Brazilian Health Informatics Department (DATASUS). Cad Saude Publica. 2019;35(9):e00032419. doi: 10.1590/0102-311X00032419
- Jalalizadeh M, Roesch HRM, Korkes F, Dien-Trinh Q, Reis LO. Prostate cancer temporal and regional trends in Brazil. Oncol Res. 2024;32(10):1565-1573. doi: 10.32604/or.2024.052179
- Huang J, Chan WC, Ngai CH, et al. Worldwide burden, risk factors, and temporal trends of ovarian cancer: A global study. Cancers (Basel). 2022;14(9):2230. doi: 10.3390/cancers14092230
- Flegar L, Kraywinkel K, Zacharis A, et al. Treatment trends for muscle-invasive bladder cancer in Germany from 2006 to 2019. World J Urol. 2022;40(7):1715-1721. doi: 10.1007/s00345-022-04017-z
- Chalfant V, Blute ML, Silberstein P. Treatment trends of muscle invasive bladder cancer: Evidence from the surveillance, epidemiology, and end results database, 1988 to 2013. Asian J Urol. 2023;10(1):9-18. doi: 10.1016/j.ajur.2021.10.002
- Cahn DB, Handorf EA, Ghiraldi EM, et al. Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer. Cancer. 2017;123(22): 4337-4345. doi: 10.1002/cncr.30900
- Mariappan P, Johnston A, Padovani L, et al. Enhanced quality and effectiveness of transurethral resection of bladder tumour in non-muscle-invasive bladder cancer: A multicentre real-world experience from Scotland’s quality performance indicators programme. Eur Urol. 2020;78(4):520-530. doi: 10.1016/j.eururo.2020.06.051
- Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020;70(5):404-423. doi: 10.3322/caac.21631
- Lee RK, Abol-Enein H, Artibani W, et al. Urinary diversion after radical cystectomy for bladder cancer: Options, patient selection, and outcomes. BJU Int. 2014;113(1):11-23. doi: 10.1111/bju.12121
- Fonseca BP, Albuquerque PC, Saldanha RF, Zicker F. Geographic accessibility to cancer treatment in Brazil: A network analysis. Lancet Reg Health Am. 2021;7:100153. doi: 10.1016/j.lana.2021.100153
- Do Nascimento LC, da Fonseca Viega SM, Menezes C, Roquini GR, Santos ITR. O SUS na vida dos brasileiros: Assistência, acessibilidade e equidade no cotidiano de usuários da Atenção Primária à Saúde. Physis (Rio J). 2020;30:e300330. doi: 10.1590/S0103-73312020300330